<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81839">
  <stage>Registered</stage>
  <submitdate>2/02/2007</submitdate>
  <approvaldate>6/02/2007</approvaldate>
  <actrnumber>ACTRN12607000107426</actrnumber>
  <trial_identification>
    <studytitle>Trial of PI-88 with Dacarbazine in patients Metastatic Melanoma</studytitle>
    <scientifictitle>A randomised phase II study to determine the safety and efficacy of PI-88 plus Dacarbazine compared to Dacarbazine alone in Patients with Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym>PR88205</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00130442</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study will be used to determine the safety and efficacy of a new drug called PI-88 when used in combination with an approved chemotherapy drug called dacarbazine (current standard treatment) in the treatment of metastatic melanoma patients.                                                                                                                                                                                 Patients eligible to participate in this study will be randomly allocated to receive the study arm: Dacarbazine (day 1 every 3 weeks 1000mg/m2 IV), plus PI- 88 (190mg) given daily via subcutaneous injection on day 1-21 inclusive in 3 week cycles.                                                                                                                                                                                            Treatment will continue for as long as benefit is shown (stable or objective response) or until patients show evidence of disease progression or are withdrawn from study treatment for other reasons. If a patient demonstrates progressive disease on the Dacarbazine alone arm they may be offered treatment with single agent PI-88 at the discretion of the Principal investigator. Patients who continue to benefit from the treatment after the initial 6 cycles of treatment will continue with the treatment. This study will continue until a minimum of 40 patients are recruited to each arm, and all patients have completed study treatment. PI-88 blocks new blood vessel growth in tumours and dacarbazine stops cancer cells from growing. the results from this study will be analysed to see if it is worthwhile for the 2 drugs to be tested in future studies involving larger numbers of melanoma patients.</interventions>
    <comparator>Dacarbazine alone (1000 mg/m2), via intravenous infusion (IV) over 1 hour on day 1 of a 3 week treatment cycle</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the proportion of patients with objective response or stable disease</outcome>
      <timepoint>After 6 treatment cycles (approximately 18 weeks of treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. non progression rate after 2 and 4 treatment cycles </outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Time to Progression</outcome>
      <timepoint>Weekly basis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Response Rate</outcome>
      <timepoint>6, 12 and 18 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Duration of response and survival</outcome>
      <timepoint>Length of time from start of treatment to treatment end and time from treatment start until death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Histologically proven metastatic melanoma2. surgery not feasible or inappropriate.3. measurable disease.4. voluntary written informed consent 5.Eastern Cooperative Oncology Group performance score 0-1. 6. at least 3 month life expectancy7. acceptable renal, liver and haematopoetic function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Central Nervous System(CNS) involvement, brain or meningeal metastases2. occular melanoma3. clinically significant non malignant disease.4. Prior or co existent malignant disease5. prior chemotherapy6. prior treatment with vaccines, biological response modifiers or radiotherapy or major surgery within the previous 4 weeks7. concomitant use of aspirin, Non Steroidal antiinflammatory drugs (NSAIDs), heaprin, low molecular weight heparin, warfarin, anti platelet drugs8. heparin or low molecular weight heparin in the previous 2 weeks.9. abnormal bleeding tendancy, history of Gastrointestinal bleeding in past 2 years, Irritable bowel sydrome.10. history of cardiac problems in past 3 months11. women who are pregnant, breast feeding or women in whom pregnacy cannot be excluded.12. allergy to anti coagulants or thrombolytic agents13. history of autoimmune bleeding disorders or evidence of Anti Heparin antibodies14. uncontrolled infection within past 4 weeks15. non compliant patients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment by "sealed opaque envelopes"</concealment>
    <sequence>simple randomisation by using a randomisation  table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>114</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Progen Pharmaceuticals Ltd</primarysponsorname>
    <primarysponsoraddress>16 Benson Street
Toowong QLD 4066</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Progen Pharmaceuticals Ltd</fundingname>
      <fundingaddress>16 Benson Street, Toowong 4066</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to determine the safety and efficacy of PI- 88 combined with dacarbazine as a first line treatment in patients with unresectable metastatic melanoma, compared to the current standard treatment of dacarbazine alone. PI-88 is a new drug which blocks new blood vessel growth in tumours, which starves the tumour of nutrients and therefore it cannot grow. Dacarbazine is a chemotherapy drug which has been used for many years to treat melanoma and it works by stopping the tumour cells from growing. It is hoped that by combining these two drugs patients will have better outcomes than if they were treated with dacarbazine alone. The results of this study will be analysed to see if it is worthwhile for the 2 drugs to be tested in future studies involving larger numbers of melanoma patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Nedlands, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec>MP/frn/Ethics 2005</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Wooloongabba, Qld</ethicaddress>
      <ethicapprovaldate />
      <hrec> 2005/31</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>X050046</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Perth WA</ethicaddress>
      <ethicapprovaldate />
      <hrec>EC RA 05/01</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress>Woodville, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec>2006 057</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress>Wodonga, Vic</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Arizona Cancer Centre</ethicname>
      <ethicaddress>Tuscon Arizona</ethicaddress>
      <ethicapprovaldate />
      <hrec>BIO # 06- 131</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Colorado Health Science Centre</ethicname>
      <ethicaddress>Denver Colorado</ethicaddress>
      <ethicapprovaldate />
      <hrec>05- 0226</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Hawkesbury Road, Westmead Hospital, Westmead, NSW, 2145</ethicaddress>
      <ethicapprovaldate>14/07/2008</ethicapprovaldate>
      <hrec>HREC 2009/5/4.1 (2781)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barbara Hicks</name>
      <address>Progen Industries Ltd
16 Benson Street
Toowong QLD 4066</address>
      <phone>+61 7 3842 3333</phone>
      <fax />
      <email>barbarah@progen-pharma.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barbara Hicks</name>
      <address>Progen Pharmaceuticals Ltd 16 Benson Street Toowong 4066 Brisbane</address>
      <phone>+61 7 3842 3333</phone>
      <fax>3720 9587</fax>
      <email>patient.enquiries@progen-pharma.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barbara Hicks</name>
      <address>Progen Pharmaceuticals Ltd, 16 Benson Street, Toowong 4066 Brisbane</address>
      <phone>+61 7 3842 3333</phone>
      <fax>3720 9587</fax>
      <email>barbarah@progen-pharma.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>